ArticleJournal of managed care & specialty pharmacy2021

The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable.

Chelsee JensenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.